Celgene antes up $195M more to stay close to Forma, adding neurodegeneration focus
Whatever Celgene $CELG learned during its lengthy collaboration with Forma Therapeutics must have been promising. The big biotech is doubling down on Forma, extending its pact and picking up an option to broaden the scope of their research work, with Forma adding new drugs focused on protein homeostasis, inflammation/immunology and neurodegeneration.
Celgene is paying Forma $195 million upfront for the extended relationship, handing Celgene ex-US rights on drug candidates through October 1, 2019.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.